An AI model can accurately flag EGFR mutations in lung adenocarcinoma using routine pathology slides, reducing the need for rapid genetic tests.
Key Details
- 1Researchers from Mount Sinai, Memorial Sloan Kettering, and collaborators published results in Nature Medicine on July 9, 2025.
- 2The AI model predicts EGFR mutations from H&E-stained pathology slides of lung adenocarcinoma.
- 3A live 'silent trial' at Memorial Sloan Kettering showed the model could reduce rapid genetic testing by over 40%.
- 4The model was trained and validated on the largest multi-institutional dataset of matched slides and sequencing results from the US and Europe.
- 5Preserving tissue by avoiding unnecessary rapid tests allows for more comprehensive genomic sequencing.
- 6Work is ongoing to broaden the model's biomarker detection and deploy it in more healthcare settings.
Why It Matters
This study demonstrates the practical integration of AI in pathology workflows, expediting precision therapy decisions and optimizing tissue usage in lung cancer diagnostics. It signals a major step toward AI-driven personalization in oncology, with potential to improve both efficiency and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
FDA Approves Johns Hopkins AI Tool for Early Sepsis Detection
FDA clears an AI-driven system developed by Johns Hopkins to detect sepsis up to 48 hours earlier and reduce mortality rates.
•EurekAlert
New AI Vision-Language Model Enhances Chest CT Diagnostics
Researchers developed an interpretable AI model that uses visual question answering to generate detailed diagnostic findings from chest CT scans, aimed at improving lung cancer diagnosis.
•EurekAlert
Optical AI Chip Boosts Real-Time Dry Eye Gland Diagnosis Accuracy
A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.